PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(09): 922-931
DOI: 10.1055/a-1912-7362
GebFra Science
Review/Übersicht

Update Mammakarzinom 2022 Teil 4 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Artikel in mehreren Sprachen: English | deutsch
Bahriye Aktas
1   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Tanja N. Fehm
2   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Manfred Welslau
3   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Volkmar Müller
4   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Diana Lüftner
5   Immanuel Hospital Märkische Schweiz & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Buckow, Germany
,
Florian Schütz
6   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Peter A. Fasching
7   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Wolfgang Janni
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Christoph Thomssen
9   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Isabell Witzel
4   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Erik Belleville
10   ClinSol GmbH & Co KG, Würzburg, Germany
,
Michael Untch
11   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Marc Thill
12   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
,
Hans Tesch
13   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
14   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Michael P. Lux
15   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany
,
Maggie Banys-Paluchowski
16   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Cornelia Kolberg-Liedtke
17   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
,
Andreas D. Hartkopf
8   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Achim Wöckel
18   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Hans-Christian Kolberg
19   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Elmar Stickeler
20   Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
,
Nadia Harbeck
21   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Andreas Schneeweiss
22   National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Für die Behandlung von Patientinnen mit fortgeschrittenem HER2-negativem, hormonrezeptorpositivem Mammakarzinom sind in den letzten Jahren einige Substanzen in die Praxis eingeführt worden. Zusätzlich sind weitere Medikamente in der Entwicklung. Im letzten Jahr sind einige Studien veröffentlicht worden, die entweder einen Vorteil für das progressions-freie Überleben oder aber auch für das Gesamtüberleben gezeigt haben. Diese Übersichtsarbeit fasst die neuesten Ergebnisse, welche auf aktuellen Kongressen oder in Fachzeitschriften veröffentlicht wurden, zusammen und ordnet sie in den klinischen Behandlungskontext ein. Insbesondere wird auf den Stellenwert einer Therapie mit CDK4/6 Inhibitoren, Trastuzumab-Deruxtecan, Sacituzumab-Govitecan und Capivasertib eingegangen. Für Trastuzumab-Deruxtecan wurde in der Destiny-Breast-04-Studie ein Gesamtüberlebensvorteil bei HER2-negativem Mammakarzinom mit einer niedrigen HER2-Expression (HER2-low expression) berichtet. Ebenso konnte ein Gesamtüberlebensvorteil in der FAKTION-Studie mit Capivasertib verzeichnet werden. Nach dem fehlenden Gesamtüberlebensvorteil für Palbociclib in der 1. Therapielinie stellt sich hier die Frage nach der klinischen Einordnung.

Schlüsselwörter

fortgeschrittenes Mammakarzinom - Chemotherapie - endokrine Therapie - Antikörper-Medikament-Konjugate


Publikationsverlauf

Eingereicht: 20. Juli 2022

Angenommen nach Revision: 31. Juli 2022

Artikel online veröffentlicht:
13. September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Wolff AC, Hammond MEH, Allison KH. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36: 2105-2122
    Suche in Google Scholar
  • 2 Ahmed N, Brawley VS, Hegde M. et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 2015; 33: 1688-1696
    CrossrefPubMedSuche in Google Scholar
  • 3 Burger MC, Zhang C, Harter PN. et al. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front Immunol 2019; 10: 2683
    CrossrefPubMedSuche in Google Scholar
  • 4 Erber R, Kailayangiri S, Huebner H. et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel) 2021; 13: 5577
    CrossrefPubMedSuche in Google Scholar
  • 5 Yu AL, Gilman AL, Ozkaynak MF. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334
    CrossrefPubMedSuche in Google Scholar
  • 6 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
    CrossrefPubMedSuche in Google Scholar
  • 7 Thill M, Friedrich M, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16: 228-235
    CrossrefPubMedSuche in Google Scholar
  • 8 Schneeweiss A, Ettl J, Luftner D. et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88-95
    Suche in Google Scholar
  • 9 Engler T, Fasching PA, Lüftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022;
    Thieme ConnectPubMedSuche in Google Scholar
  • 10 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022;
    CrossrefPubMedSuche in Google Scholar
  • 11 Baselga J, Im SA, Iwata H. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 904-916
    CrossrefPubMedSuche in Google Scholar
  • 12 Andre F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
    CrossrefPubMedSuche in Google Scholar
  • 13 Vanhaesebroeck B, Perry MWD, Brown JR. et al. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov 2021; 20: 741-769
    CrossrefPubMedSuche in Google Scholar
  • 14 Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol 2022; 19: 471-485
    CrossrefPubMedSuche in Google Scholar
  • 15 Jones RH, Casbard A, Carucci M. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020; 21: 345-357
    CrossrefPubMedSuche in Google Scholar
  • 16 Jones RH, Casbard AC, Carucci M. et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis. J Clin Oncol 2022; 40: 1005
    CrossrefPubMedSuche in Google Scholar
  • 17 clinicaltrials.gov. Capivasertib+Fulvestrant vs. Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291). 2022. Accessed June 27, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04305496
    PubMed
  • 18 clinicaltrials.gov. Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). (CAPItello-292). 2022. Accessed June 27, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04862663
    PubMed
  • 19 Neven P, Fasching PA, Chia S. et al. Updated overall survival (OS) results from the first-line (1 L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Ann Oncol 2022; 33 (Suppl. 03) S194-S223
    CrossrefPubMedSuche in Google Scholar
  • 20 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
    CrossrefPubMedSuche in Google Scholar
  • 21 Finn RS, Rugo HS, Dieras VC. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol 2022; 40: LBA1003
    CrossrefPubMedSuche in Google Scholar
  • 22 Bidard F, Hardy-Bessard A, Bachelot T. et al. Fulvestrant-palbociclib vs. continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. San Antonio Breast Cancer Symposium 2021; 2021: GS3-05
    PubMedSuche in Google Scholar
  • 23 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022. Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05362760
    PubMed
  • 24 Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018; 9: 28989-29006
    CrossrefPubMedSuche in Google Scholar
  • 25 Zaman S, Jadid H, Denson AC. et al. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther 2019; 12: 1781-1790
    CrossrefPubMedSuche in Google Scholar
  • 26 Vranic S, Gatalica Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn J Basic Med Sci 2022; 22: 14-21
    CrossrefPubMedSuche in Google Scholar
  • 27 Liu X, Zhou T, Wang Y. et al. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer. Onco Targets Ther 2022; 15: 509-520
    CrossrefPubMedSuche in Google Scholar
  • 28 Hurvitz SA, Tolaney SM, Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-06
    PubMedSuche in Google Scholar
  • 29 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianʼs choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001
    CrossrefPubMedSuche in Google Scholar
  • 30 Clinicaltrials.gov. Study of Trastuzumab Deruxtecan (T-DXd) vs. Investigatorʼs Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06). 2022. Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04494425
    PubMed
  • 31 clinicaltrials.gov. Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1 m Before Progression (SERENA-6) (SERENA-6). 2021. Accessed October 24, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04964934
    PubMed
  • 32 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022. Accessed July 16, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05452213
    PubMed
  • 33 Fasching PA. CAPTOR-BC: Gemeinsam Forschen für eine individualisierte Ribociclib-Therapie Senologiekongress 2022. 2022. Accessed June 26, 2022 at: https://www.senologiekongress.de/xconfig/upload/files/Programme/Seno2022_Programm.pdf
    PubMed
  • 34 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
    CrossrefPubMedSuche in Google Scholar
  • 35 European Medicines Agency. Verzenios Summary of product characteristics (SmPC). 2022. Accessed March 26, 2022 at: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_de.pdf
    PubMed
  • 36 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
    CrossrefPubMedSuche in Google Scholar
  • 37 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
    CrossrefPubMedSuche in Google Scholar
  • 38 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedSuche in Google Scholar
  • 39 Tripathy D, Im S-A, Colleoni M. et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res 2021; 81: PD2-04-PD02-04
    CrossrefPubMedSuche in Google Scholar
  • 40 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;
    CrossrefPubMedSuche in Google Scholar
  • 41 Fasching PA, Esteva FJ, Pivot X. et al. Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3. Ann Oncol 2018; 29: viii90-viii121
    CrossrefPubMedSuche in Google Scholar
  • 42 Slamon DJ, Neven P, Chia S. et al. Overall Survival Results from the Phase 3 MONALEESA-3 Study of Fulvestrant ± Ribociclib in Postmenopausal Patients With HR+/HER2− Advanced Breast Cancer. Ann Oncol 2019; 30 (Suppl. 05) v851-v934
    CrossrefPubMedSuche in Google Scholar
  • 43 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedSuche in Google Scholar
  • 44 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedSuche in Google Scholar
  • 45 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
    CrossrefPubMedSuche in Google Scholar
  • 46 Sledge jr. GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedSuche in Google Scholar
  • 47 Cristofanilli M, Rugo HS, Im S-A. et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. J Clin Oncol 2021; 39: 1000
    CrossrefPubMedSuche in Google Scholar
  • 48 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
    CrossrefPubMedSuche in Google Scholar
  • 49 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
    CrossrefPubMedSuche in Google Scholar
  • 50 Xu B, Zhang Q, Zhang P. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 2021; 27: 1904-1909
    CrossrefPubMedSuche in Google Scholar
  • 51 Hein A, Hartkopf AD, Emons J. et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer 2021; 155: 1-12
    CrossrefPubMedSuche in Google Scholar
  • 52 Guyot P, Ades AE, Ouwens MJ. et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9
    CrossrefPubMedSuche in Google Scholar
  • 53 Yi Z, Ma F. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. J Breast Cancer 2017; 20: 321-326
    CrossrefPubMedSuche in Google Scholar